Clinical Trial Detail

NCT ID NCT04256941
Title Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

estrogen-receptor positive breast cancer

progesterone-receptor positive breast cancer

Therapies

Abemaciclib + Fulvestrant

Fulvestrant + Palbociclib

Letrozole + Palbociclib

Fulvestrant + Ribociclib

Abemaciclib + Letrozole

Anastrozole + Palbociclib

Anastrozole + Ribociclib

Letrozole + Ribociclib

Abemaciclib + Anastrozole

Age Groups: adult senior

No variant requirements are available.